The Trump Administration’s proposed $4.8 trillion budget for fiscal 2021 features plenty of reductions to spending for Medicare, Medicaid and Social Security. Naturally, this has Democrats and elder advocates up in arms.
The proposal would slash Medicare by $850 billion, Medicaid by $920 billion and Social Security by $30 billion over the next decade, according to The Washington Post. It also includes cuts to Children’s Health Insurance programs, despite previous statements by the president that entitlements would remain untouched. Continue reading
The U.S. Supreme Court recently agreed to hear a case that pits two groups on opposite sides of the debate over prescription drug costs: community pharmacists and pharmacy benefit managers.
In the case, Rutledge v. Pharmaceutical Care Management Association, the court will consider whether the federal Employee Retirement Income Security Act (ERISA) of 1974 pre-empts an Arkansas law regulating PBMs’ drug-reimbursement rates.
With the 10th anniversary of the Affordable Care Act approaching next month (March 23), I want to flag this video from the summer of 2018, when KHN’s Julie Rovner interviewed the five committee chairs who shepherded the law through Congress.
This was the first time that former Sens. Max Baucus (D-Mont.) and Chris Dodd (D-Conn.) and former Reps. Henry Waxman (D-Calif.) and George Miller (D-Calif.) and retiring Rep. Sander Levin (D-Mich.) had gathered for a public retrospective. All but Levin had retired by then and he left Congress soon after the event, which took place during the Aspen Ideas Festival’s health portion (then called Spotlight Health and now Ideas Health.) Continue reading
The Federal Trade Commission and State of New York late last month filed a lawsuit against Martin Shkreli, charging that Shkreli and Vyera Pharmaceuticals raised the price of the life-saving drug Daraprim by more than 4,000% and worked to corner the market for such drugs.
“The joint action accused Shkreli and Vyera Pharmaceuticals, formerly known as Turing Pharmaceuticals, of scheming to ‘illegally’ prevent would-be generic competitors from selling a version of Daraprim,” as Stat’s Ed Silverman reported on Jan. 27. After acquiring the drug in 2015, Shkreli, dubbed the “Pharma Bro,” and Turing raised the list price of the medication from $17.50 per tablet to $750, he added. Continue reading
The Supreme Court has declined to take up, on an expedited basis, Texas v. Azar, the conservative states’ lawsuit against the ACA. That doesn’t mean that the case — which argues for scrapping the whole 2010 health law now that the individual mandate penalty has been zeroed out — will never reach the Supreme Court. But it’s now highly unlikely that the high court will rule during President Donald Trump’s re-election campaign.
The Supreme Court doesn’t usually take up cases until they’ve worked their way through the lower courts. But as we told you recently, it wasn’t 100 percent clear that they’d follow that tradition in this case. Continue reading
Under the most usual course of events, the Supreme Court would not consider (again) the fate of the Affordable Care Act smack in the midst of the 2020 presidential elections.
But we aren’t living amid “usual” course of events. A coalition of state attorneys general wants the legal process speeded up. And while it’s not that likely that the high court will agree, it’s not impossible either.
In December the Fifth Circuit Court of Appeals voided the ACA’s individual mandate. But it didn’t agree with the earlier District Court ruling from December 2018 that because the mandate is unconstitutional, the whole law is invalid. Continue reading